198 related articles for article (PubMed ID: 36790041)
1. Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data.
Danese S; Tran J; D'Haens G; Rubin DT; Aoyama N; Zhou W; Ilo D; Yao X; Sanchez Gonzalez Y; Panaccione R
Inflamm Bowel Dis; 2023 Nov; 29(11):1723-1729. PubMed ID: 36790041
[TBL] [Abstract][Full Text] [Related]
2. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
3. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.
Ghosh S; Sanchez Gonzalez Y; Zhou W; Clark R; Xie W; Louis E; Loftus EV; Panes J; Danese S
J Crohns Colitis; 2021 Dec; 15(12):2022-2030. PubMed ID: 34107013
[TBL] [Abstract][Full Text] [Related]
4. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Loftus EV; Colombel JF; Takeuchi K; Gao X; Panaccione R; Danese S; Dubinsky M; Schreiber S; Ilo D; Finney-Hayward T; Zhou W; Phillips C; Gonzalez YS; Shu L; Yao X; Zhou Q; Vermeire S
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2347-2358.e6. PubMed ID: 36464141
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Vermeire S; Danese S; Zhou W; Ilo D; Klaff J; Levy G; Yao X; Chen S; Sanchez Gonzalez Y; Hébuterne X; Lindsay JO; Higgins PDR; Cao Q; Nakase H; Colombel JF; Loftus EV; Panaccione R
Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):976-989. PubMed ID: 37683686
[TBL] [Abstract][Full Text] [Related]
6. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.
Panés J; Loftus EV; Higgins PDR; Lindsay JO; Zhou W; Yao X; Ilo D; Phillips C; Tran J; Sanchez Gonzalez Y; Vermeire S
Inflamm Bowel Dis; 2023 Sep; 29(9):1421-1430. PubMed ID: 36645051
[TBL] [Abstract][Full Text] [Related]
7. Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.
Raine T; Ishiguro Y; Rubin DT; Finney-Hayward T; Vladea R; Liu J; Phillips C; Cheng E; Targownik L; Loftus EV
J Crohns Colitis; 2024 May; 18(5):695-707. PubMed ID: 37942921
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Panaccione R; Danese S; Zhou W; Klaff J; Ilo D; Yao X; Levy G; Higgins PDR; Loftus EV; Chen S; Gonzalez YS; Leonard C; Hébuterne X; Lindsay JO; Cao Q; Nakase H; Colombel JF; Vermeire S
Aliment Pharmacol Ther; 2024 Feb; 59(3):393-408. PubMed ID: 38010661
[TBL] [Abstract][Full Text] [Related]
10. Impact of upadacitinib induction and maintenance therapy on health-related quality of life, fatigue, and work productivity in patients with moderately-to-severely active Crohn's disease.
Ghosh S; Feagan BG; Parra RS; Lopes S; Steinlauf A; Kakuta Y; Joshi N; Lee WJ; Lacerda AP; Zhou Q; Xuan S; Kligys K; Shukla N; Louis E
J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38835235
[TBL] [Abstract][Full Text] [Related]
11. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients.
Ponce-Bobadilla AV; Stodtmann S; Eckert D; Zhou W; Liu W; Mohamed MF
Clin Pharmacokinet; 2023 Jan; 62(1):101-112. PubMed ID: 36571701
[TBL] [Abstract][Full Text] [Related]
12. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Maintenance Therapy With Upadacitinib on Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 U-ACHIEVE Maintenance Results.
Gastroenterol Hepatol (N Y); 2022 Apr; 18(4 Suppl 1):5-6. PubMed ID: 35610994
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
[TBL] [Abstract][Full Text] [Related]
15. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
[TBL] [Abstract][Full Text] [Related]
16. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
17. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R
Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829
[TBL] [Abstract][Full Text] [Related]
18. Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies.
Long MD; Schreiber S; Hibi T; Gibble TH; Fisher DA; Park G; Moses RE; Higgins PDR; Lindsay JO; Lee SD; Escobar R; Jairath V
Crohns Colitis 360; 2024 Jan; 6(1):otae001. PubMed ID: 38313767
[TBL] [Abstract][Full Text] [Related]
19. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis.
Law CCY; Kayal M; Mehandru S; Colombel JF
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):109-117. PubMed ID: 36681073
[TBL] [Abstract][Full Text] [Related]
20. Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
Dubinsky MC; Clemow DB; Hunter Gibble T; Li X; Vermeire S; Hisamatsu T; Travis SPL
Crohns Colitis 360; 2023 Jan; 5(1):otac044. PubMed ID: 36777368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
